Stifel Maintains Buy on Trevi Therapeutics, Raises Price Target to $18
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Annabel Samimy maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $15 to $18.
Stifel analyst Annabel Samimy maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $15 to $18.